Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Medicinal Products

Dáil Éireann Debate, Thursday - 19 February 2026

Thursday, 19 February 2026

Ceisteanna (590)

Ken O'Flynn

Ceist:

590. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment, clinical safety review, or value-for-money analysis was conducted in relation to the ongoing shortages of salbutamol nebules during 2024 and 2025; whether contingency procurement arrangements were activated; and what governance structures are in place to ensure uninterrupted reimbursement access for essential respiratory medicines for medical card holders. [13631/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Roinn